


What is claimed is:

1. A compound, or salt or tautomer thereof, according to Formula (I):



(I)

Wherein

n is 0, 1 or 2;

R is hydrogen, C_1 - C_4 alkyl, or hydroxy C_1 - C_4 alkyl;

R^1 is halogen, hydroxy, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, halo C_1 - C_6 alkyl, hydroxy C_1 - C_6 alkyl, amino C_1 - C_6 alkyl, C_1 - C_6 alkoxy C_1 - C_6 alkyl, C_1 - C_6 alkoxy C_1 - C_6 alkoxy, C_3 - C_6 cycloalkyl C_1 - C_6 alkoxy, halo C_1 - C_6 alkoxy, $-S(O)_pC_1$ - C_6 alkyl, $-CH_2NHC(O)C_1$ - C_4 alkyl or $-OCH_2C(O)R^7$,

p is 0, 1, or 2;

R^2 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy C_1 - C_6 alkyl or halogen;

R^3 is hydrogen, halogen, cyano, C_1 - C_4 alkyl, halo C_1 - C_4 alkyl, $-CH_2C(O)R^7$, phenyl or 5 or 6 member heteroaryl having 1, 2 or 3 ring heteroatoms independently selected from N, O or S, wherein the phenyl or heteroaryl is optionally substituted with 0, 1, or 2 C_1 - C_4 alkyl groups, and wherein alkyl and haloalkyl optionally substituted with 0 or 1 hydroxy;

R^4 is phenyl, naphthyl or heteroaryl, where the heteroaryl is a five or six member heteroaryl having 1, 2 or 3 ring heteroatoms independently selected from N, O or S, and where the phenyl or heteroaryl is optionally substituted by R^5 and further substituted by 0 or 1 substituents selected from halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, hydroxy C_1 - C_4 alkyl, hydroxy, and cyanomethyl;

R^5 is $-C(O)R^8$, $-CH_2C(O)R^8$, R^9 , $-C(O)NHSO_2C_1$ - C_4 alkyl, $-SO_2NHC(O)C_1$ - C_4 alkyl, $-SO_2N(H)_m(C_1$ - C_4 alkyl) $_{2-m}$, $-SO_2C_1$ - C_4 alkyl, cyano, halogen, hydroxy C_1 - C_4 alkyl and 5 member heteroaryl having 1-4 ring nitrogen atoms and 0 or 1 ring sulfur or oxygen atoms;

m is 0, 1, or 2;

W is O or C(R⁶)₂;

R⁶ is independently selected at each occurrence from the group consisting of hydrogen, hydroxy, amino, mono- and di- C₁-C₄alkylamino, C₁-C₄alkyl, hydroxyC₁-C₄alkyl, cyanoC₁-C₄alkyl or C₁-C₄alkoxy; or

C(R⁶)₂, taken in combination, form a spirocyclic carbocycle having 3 to 6 ring atoms;


R⁷ is hydroxy, C₁-C₄alkoxy, amino or mono- and di-C₁-C₄alkylamino;

R⁸ is hydroxy, C₁-C₄alkoxy, amino or a 5 to 7 member saturated heterocycle having 1, 2, or 3 ring heteroatoms independently selected from N, O or S; or


R⁸ is mono- and di-C₁-C₄alkylamino which is unsubstituted or substituted with halogen, hydroxy or C₁-C₄alkyl; and

R⁹ is a 5 membered heteroaryl having 1 to 4 ring nitrogen atoms and 0 or 1 ring oxygen or sulfur atoms, which heterocycle is optionally substituted by 0 to 2 C₁-C₄alkyl groups.

2. A compound of claim 1, or salt or tautomer thereof, wherein n is 1.
3. The compound of either claim 1 or claim 2, or a salt or tautomer thereof, wherein W is CHR⁶ or C(CH₃)R⁶.
4. The compound of any one of claims 1 to 3, or a salt or tautomer thereof, wherein R¹ is hydrogen, C₁-C₄alkyl, C₁-C₄alkoxy, or cyclopropyl.
5. The compound of any one of claims 1 to 4, or a salt or tautomer thereof, wherein R² is methyl.
6. The compound of any one of claims 1 to 5, or a salt or tautomer thereof, wherein R³ is hydrogen, halogen or C₁-C₄alkyl.
7. The compound of any one of claims 1 to 6, or a salt or tautomer thereof, wherein R³ is hydrogen.
8. The compound of any one of claims 1 to 7, or salt or tautomer thereof, according to Formula (IIa) or (IIb):




(IIa) or




(IIb).

9. The compound of any one of claims 1 to 8, or salt or tautomer thereof, according to Formula (IIIa) or (IIIb):



(IIIa) or




(IIIb)


Wherein X is N or CH.

10. The compound of any one of claims 1 to 8, or a salt or tautomer thereof, wherein R^4 is pyridin-3-yl which is substituted para to the piperidine ring with R^5 .
11. The compound of any one of claims 1 to 8, or a salt or tautomer thereof, wherein R^4 is phenyl substituted para to the piperidine ring with R^5 and optionally substituted with fluoro, methoxy, hydroxymethyl or hydroxy.
12. The compound of claim 11, or a salt or tautomer thereof, wherein R^4 is phenyl substituted para to the piperidine ring with R^5 .

13. The compound of any one of claims 1 to 8, or salt or tautomer thereof, according to Formula (IVa) or (IVb):



(IVa) or



(IVb).

14. The compound of any one of claims 1 to 13, or a salt or tautomer thereof, wherein R⁵ is CO₂H, CO₂NH₂, SO₂NH₂ or tetrazolyl.

15. The compound of claim 1, or a salt or tautomer thereof, which compound is selected from the group consisting of

- w1-((5,7-dimethyl-1H-indol-4-yl)methyl)-2-phenylpiperidin-4-ol;
- 4-((4-methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1H-indole;
- 5,7-dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1H-indole;
- 1-((5,7-dimethyl-1H-indol-4-yl)methyl)-2-phenyl-piperidin-4-yl)methanol;
- 4-(1-((5,7-dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzenesulfonamide;
- 3-(1-((5,7-dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzenesulfonamide;
- 4-(1-((5,7-dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)-N-methylbenzenesulfonamide;
- 3-(1-((5,7-dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)-N-methylbenzenesulfonamide;
- 4-((2-(4-fluorophenyl)-4-methoxypiperidin-1-yl)methyl)-5,7-dimethyl-1H-indole;
- (1-((5,7-dimethyl-1H-indol-4-yl)methyl)-2-phenylpiperidin-2-yl)methanol;
- (4-(1-((5,7-dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanol;
- 5,7-dimethyl-4-((2-(4-(methylsulfonyl)phenyl)piperidin-1-yl)methyl)-1H-indole;
- 4-((2-(4-(2H-tetrazol-5-yl)phenyl)piperidin-1-yl)methyl)-5,7-dimethyl-1H-indole;
- 1-((5,7-dimethyl-1H-indol-4-yl)methyl)-2-phenylpiperidin-4-amine;
- 4-(1-((5,7-dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzamide;

4-(1-((5-chloro-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzamide;
4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzamide;
4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-hydroxypiperidin-2-yl)benzoic acid;
4-(1-((5-chloro-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
methyl 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate;
4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-2-fluorobenzoic acid;
4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)pyrrolidin-2-yl)benzoic acid;
5-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)picolinic acid;
4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-3-methoxybenzoic acid;
4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
5-methoxy-7-methyl-4-((2-(pyridin-4-yl)piperidin-1-yl)methyl)-1*H*-indole;
5-methoxy-7-methyl-4-((2-(pyridin-3-yl)piperidin-1-yl)methyl)-1*H*-indole;
3-fluoro-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
4-(4-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)morpholin-3-yl)benzoic acid;
6-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)nicotinic acid;
4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-propoxypiperidin-2-yl)benzoic acid;
4-(4-hydroxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-3-methylbenzoic acid;
4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-5-methylpiperidin-2-yl)benzoic acid;
4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-ethylpiperidin-2-yl)benzoic acid;
2-(4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)acetic acid;
2-(3-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)acetic acid;
5-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)picolinic acid;
2-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)thiazole-4-carboxylic acid;
2-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-4-methylthiazole-5-carboxylic acid;
3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)azepan-2-yl)benzoic acid;
4-((2-(4-(1*H*-pyrazol-4-yl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;
4-((2-(4-(1*H*-pyrazol-3-yl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;
4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-1-naphthoic acid;
1-(2,2,2-trifluoro-1-(5-methoxy-7-methyl-1*H*-indol-4-yl)ethyl)piperidin-2-yl)benzoic acid;
2-methoxy-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
2-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-4-yl)acetonitrile;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoic acid;
4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
5-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)picolinic acid;
4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4,4-dimethylpiperidin-2-yl)benzoic acid;
4-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzonitrile;
4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
4-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic acid;
4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic acid;
4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
4-(5-hydroxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-*N*-methyl-2-phenylpiperidin-4-amine;
(4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanamine;
(4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanol;
4-((2-(3-(2*H*-tetrazol-5-yl)phenyl)piperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole;
3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
(3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanol;
(4-((2-(4-(1*H*-tetrazol-5-yl)phenyl)-4-ethoxypiperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;
4-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-(methylsulfonyl)benzamide;
4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-methylbenzamide;
4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N,N*-dimethylbenzamide;
(4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)(morpholino)methanone;
N-(2-hydroxyethyl)-4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-(2-methoxyethyl)benzamide;

N-((4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)sulfonyl)acetamide;
4-(6-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-6-azaspiro[2.5]octan-5-yl)benzoic acid;
4-ethyl-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
ethyl 4-((2*S*,4*R*)-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoate;
ethyl 4-((2*S*,4*S*)-4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoate and
salts, stereoisomers and tautomers thereof.

In a sixteenth embodiment, the invention provides compounds, salts thereof and tautomers thereof of embodiment 1 in which compound is selected from the group consisting of:

(-)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-4-ol (diastereomer-2);
(±)-4-((4-methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole (diastereomer-1);
(-)-4-((4-methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole (diastereomer-2);
(±)-5,7-dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1*H*-indole;
(±)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenyl-piperidin-4-yl)methanol (diastereomer-1);
(±)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenyl-piperidin-4-yl)methanol (diastereomer-2);
(±)-4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzenesulfonamide;
(±)-3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzenesulfonamide;
(±)-4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-methylbenzenesulfonamide;
(±)-3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-methylbenzenesulfonamide;
(±)-4-((2-(4-fluorophenyl)-4-methoxypiperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole;
(±)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-2-yl)methanol;
(4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanol;
(±)-5,7-dimethyl-4-((2-(4-(methylsulfonyl)phenyl)piperidin-1-yl)methyl)-1*H*-indole;
(±)-4-((2-(4-(2*H*-tetrazol-5-yl)phenyl)piperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole;
(±)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-4-amine (diastereomer-1);
(±)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-4-amine (diastereomer-2);
(±)-4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
(±)-4-(1-((5-chloro-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
(±)-4-(*rel*-(2*S*,4*S*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzamide;
(±)-4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzamide
(single diastereomer);
(±)-4-(*rel*-(2*S*,4*S*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-hydroxypiperidin-2-yl)benzoic acid;
(±)-4-(*rel*-(2*S*,4*R*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-hydroxypiperidin-2-yl)benzoic acid;
(±)-4-(1-((5-chloro-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(±)-methyl 4-(*rel*-(2*S*,4*S*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate;

(±)-methyl 4-(*rel*-(2*S*,4*R*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate;
(-)-(S)-4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-2-fluorobenzoic acid;
(-)-(S)-4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(±)-4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)pyrrolidin-2-yl)benzoic acid;
(-)-(S)-5-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)picolinic acid;
(-)-(S)-4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-3-methoxybenzoic acid;
(-)-(S)-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(±)-5-methoxy-7-methyl-4-((2-(pyridin-4-yl)piperidin-1-yl)methyl)-1*H*-indole;
(±)-5-methoxy-7-methyl-4-((2-(pyridin-3-yl)piperidin-1-yl)methyl)-1*H*-indole;
(+)-(S)-3-fluoro-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(-)-(R)-4-(4-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)morpholin-3-yl)benzoic acid;
(-)-(S)-6-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)nicotinic acid;
(-)-4-((2*S*,4*S*)-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-propoxypiperidin-2-yl)benzoic acid;
(-)-4-((2*S*,4*S*)-4-hydroxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(±)-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-3-methylbenzoic acid;
(±)-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-5-methylpiperidin-2-yl)benzoic acid (single diastereomer);
(±)-4-(*rel*-(2*S*,4*R*)-4-ethyl-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(±)-2-(4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)acetic acid;
(±)-2-(3-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)acetic acid;
(±)-5-(*rel*-(2*S*,4*S*)-1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)picolinic acid;
(±)-2-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)thiazole-4-carboxylic acid;
(±)-2-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-4-methylthiazole-5-carboxylic acid;
(±)-3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(±)-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)azepan-2-yl)benzoic acid;
(-)-(S)-4-((2-(4-(1*H*-pyrazol-4-yl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;
(-)-(S)-4-((2-(4-(1*H*-pyrazol-3-yl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;
(±)-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-1-naphthoic acid;
4-((2*S*)-1-(2,2,2-trifluoro-1-(5-methoxy-7-methyl-1*H*-indol-4-yl)ethyl)piperidin-2-yl)benzoic acid (diastereomer-1);
(±)-2-methoxy-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(±)-4-(6-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-6-azaspiro[2.5]octan-5-yl)benzoic acid;

(±)-4-(*rel*-(2*S*,4*S*)-4-ethyl-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(±)-2-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-4-yl)acetonitrile (diastereomer-1);
(+)-4-((2*S*,4*R*)-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoic acid;
(-)-4-((2*R*,4*S*)-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoic acid;
(+)-4-((2*R*,4*R*)-4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(-)-4-((2*S*,4*S*)-4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(-)-5-(*rel*-(2*S*,4*S*)-4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)picolinic acid;
(+)-5-(*rel*-(2*S*,4*S*)-4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)picolinic acid;
(+)-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4,4-dimethylpiperidin-2-yl)benzoic acid;
(-)-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4,4-dimethylpiperidin-2-yl)benzoic acid;
(-)-4-(*rel*-(2*S*,4*S*)-4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzonitrile;
(+)-4-(*rel*-(2*S*,4*S*)-4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
(+)-4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(-)-4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
(+)-4-((2*S*,4*S*)-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl))benzoic acid;
(-)-4-((2*R*,4*R*)-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl))benzoic acid;
(+)-4-(*rel*-(2*S*,4*S*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic acid;
(-)-4-(*rel*-(2*S*,4*S*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic acid;
(+)-4-(*rel*-(2*S*,4*S*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
(-)-4-(*rel*-(2*S*,4*S*)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
(-)-4-(*rel*-(2*S*,4*S*)-1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic acid;
(+)-4-(*rel*-(2*S*,4*S*)-1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic acid;
(+)-4-(*rel*-(2*S*,4*S*)-1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
(-)-4-(*rel*-(2*S*,4*S*)-1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
(±)-4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (diastereomer-1);
(±)-4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide (diastereomer-1);

(±)-4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (diastereomer-2);

(±)-4-(5-hydroxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (diastereomer-1);

(±)-4-(5-hydroxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (diastereomer-2);

(±)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-*N*-methyl-2-phenylpiperidin-4-amine (diastereomer-1);

(±)-1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-*N*-methyl-2-phenylpiperidin-4-amine (diastereomer-2);

(±)-4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenylmethanamine;

4-((2*S*,4*S*)-4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenylmethanol;

(±)-4-(2-(3-(2*H*-tetrazol-5-yl)phenyl)piperidin-1-yl)methyl-5,7-dimethyl-1*H*-indole;

(±)-3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;

(±)-3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenylmethanol;

(±)-4-(*rel*-(2*S*,4*S*)-(2-(4-(1*H*-tetrazol-5-yl)phenyl)-4-ethoxypiperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;

(+)-4-((2*S*,4*S*)-4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-(methylsulfonyl)benzamide;

4-((2*S*,4*S*)-4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-methylbenzamide;

4-((2*S*,4*S*)-4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N,N*-dimethylbenzamide;

4-((2*S*,4*S*)-4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl(morpholino)methanone;

N-(2-hydroxyethyl)-4-((2*S*,4*S*)-4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;

4-((2*S*,4*S*)-4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-(2-methoxyethyl)benzamide;

(±)-*N*-((4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)sulfonyl)acetamide;

ethyl 4-((2*S*,4*R*)-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoate;

ethyl 4-((2*S*,4*S*)-4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoate and salts, stereoisomers and tautomers thereof.


16. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and a therapeutically effective amount of a compound of any one of claims 1-15.
17. A combination, in particular a pharmaceutical combination, comprising a therapeutically effective amount of the compound according to any one of claims 1-15 and a second therapeutically active agent.
18. A method of modulating complement alternative pathway activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1-15.
19. A method of treating a disorder or a disease in a subject mediated by complement activation, in particular mediated by activation of the complement alternative pathway, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1-15.
20. The method of claim 19, in which the disease or disorder is selected from the group consisting of age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-choroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus, nonarteritic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of inappropriate or undesirable complement activation, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, neural regeneration, dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune

vasculitis, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis and obesity.

21. A method of treating age related macular degeneration comprising administering to a subject in need thereof an effective amount of a composition comprising a compound of any one of claims 1-15.
22. A compound according to any one of claims 1-15, for use as a medicament.
23. Use of a compound according to any one of claims 1-15, in the manufacture of a medicament for the treatment of a disorder or disease in a subject mediated by complement activation or activation of the complement alternative pathway.
24. Use of a compound according to any one of claims 1-15, for the treatment of age-related macular degeneration.
25. A compound of claim 1 to 15 for use in the treatment of age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-choroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus, nonarteritic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of inappropriate or undesirable complement activation, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, neural regeneration, dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis and obesity.

What is claimed is:

1. A compound, or salt or tautomer thereof, according to Formula (I):



(I)

Wherein

n is 0, 1 or 2;

R is hydrogen, C₁-C₄alkyl, or hydroxyC₁-C₄alkyl;

R¹ is halogen, hydroxy, C₁-C₆alkyl, C₂-C₆alkenyl, C₃-C₆cycloalkyl, C₁-C₆alkoxy, haloC₁-C₆alkyl, hydroxyC₁-C₆alkyl, aminoC₁-C₆alkyl, C₁-C₆alkoxyC₁-C₆alkyl, C₁-C₆alkoxyC₁-C₆alkoxy, C₃-C₆cycloalkylC₁-C₆alkoxy, haloC₁-C₆alkoxy, -S(O)_pC₁-C₆alkyl, -CH₂NHC(O)C₁-C₄alkyl or -OCH₂C(O)R⁷,

p is 0, 1, or 2;

R² is C₁-C₆alkyl, C₁-C₆alkoxy, hydroxyC₁-C₆alkyl or halogen;

R³ is hydrogen, halogen, cyano, C₁-C₄alkyl, haloC₁-C₄alkyl, -CH₂C(O)R⁷, phenyl or 5 or 6 member heteroaryl having 1, 2 or 3 ring heteroatoms independently selected from N, O or S, wherein the phenyl or heteroaryl is optionally substituted with 0, 1, or 2 C₁-C₄alkyl groups, and wherein alkyl and haloalkyl optionally substituted with 0 or 1 hydroxy;

R⁴ is phenyl, naphthyl or heteroaryl, where the heteroaryl is a five or six member heteroaryl having 1, 2 or 3 ring heteroatoms independently selected from N, O or S, and where the phenyl or heteroaryl is optionally substituted by R⁵ and further substituted by 0 or 1 substituents selected from halogen, C₁-C₄alkyl, C₁-C₄alkoxy, hydroxy C₁-C₄alkyl, hydroxy, and cyanomethyl;

R⁵ is -C(O)R⁸, -CH₂C(O)R⁸, R⁹, -C(O)NHSO₂C₁-C₄alkyl, -SO₂NHC(O)C₁-C₄alkyl, -SO₂N(H)_m(C₁-C₄alkyl)_{2-m}, -SO₂C₁-C₄alkyl, cyano, halogen, hydroxyC₁-C₄alkyl and 5 member heteroaryl having 1-4 ring nitrogen atoms and 0 or 1 ring sulfur or oxygen atoms;

m is 0, 1, or 2;

W is O or C(R⁶)₂;

R⁶ is independently selected at each occurrence from the group consisting of hydrogen, hydroxy, amino, mono- and di- C₁-C₄alkylamino, C₁-C₄alkyl, hydroxyC₁-C₄alkyl, cyanoC₁-C₄alkyl or C₁-C₄alkoxy; or

C(R⁶)₂, taken in combination, form a spirocyclic carbocycle having 3 to 6 ring atoms;


R⁷ is hydroxy, C₁-C₄alkoxy, amino or mono- and di-C₁-C₄alkylamino;

R⁸ is hydroxy, C₁-C₄alkoxy, amino or a 5 to 7 member saturated heterocycle having 1, 2, or 3 ring heteroatoms independently selected from N, O or S; or


R⁸ is mono- and di-C₁-C₄alkylamino which is unsubstituted or substituted with halogen, hydroxy or C₁-C₄alkyl; and

R⁹ is a 5 membered heteroaryl having 1 to 4 ring nitrogen atoms and 0 or 1 ring oxygen or sulfur atoms, which heterocycle is optionally substituted by 0 to 2 C₁-C₄alkyl groups.

2. A compound of claim 1, or salt or tautomer thereof, wherein n is 1.
3. The compound of either claim 1 or claim 2, or a salt or tautomer thereof, wherein W is CHR⁶ or C(CH₃)R⁶.
4. The compound of any one of claims 1 to 3, or a salt or tautomer thereof, wherein R¹ is hydrogen, C₁-C₄alkyl, C₁-C₄alkoxy, or cyclopropyl.
5. The compound of any one of claims 1 to 4, or a salt or tautomer thereof, wherein R² is methyl.
6. The compound of any one of claims 1 to 5, or a salt or tautomer thereof, wherein R³ is hydrogen, halogen or C₁-C₄alkyl.
7. The compound of any one of claims 1 to 6, or a salt or tautomer thereof, wherein R³ is hydrogen.
8. The compound of any one of claims 1 to 7, or salt or tautomer thereof, according to Formula (IIa) or (IIb):




(IIa) or




(IIb).

9. The compound of any one of claims 1 to 8, or salt or tautomer thereof, according to Formula (IIIa) or (IIIb):



(IIIa) or



(IIIb)


Wherein X is N or CH.

10. The compound of any one of claims 1 to 8, or a salt or tautomer thereof, wherein R⁴ is pyridin-3-yl which is substituted para to the piperidine ring with R⁵.


11. The compound of any one of claims 1 to 8, or a salt or tautomer thereof, wherein R⁴ is phenyl substituted para to the piperidine ring with R⁵ and optionally substituted with fluoro, methoxy, hydroxymethyl or hydroxy.

12. The compound of claim 11, or a salt or tautomer thereof, wherein R⁴ is phenyl substituted para to the piperidine ring with R⁵.

13. The compound of any one of claims 1 to 8, or salt or tautomer thereof, according to Formula (IVa) or (IVb):



(IVa) or



(IVb).

14. The compound of any one of claims 1 to 13, or a salt or tautomer thereof, wherein R⁵ is CO₂H, CO₂NH₂, SO₂NH₂ or tetrazolyl.

15. The compound of claim 1, or a salt or tautomer thereof, which compound is selected from the group consisting of

- w1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-4-ol;
- 4-((4-methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole;
- 5,7-dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1*H*-indole;
- 1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenyl-piperidin-4-yl)methanol;
- 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzenesulfonamide;
- 3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzenesulfonamide;
- 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-methylbenzenesulfonamide;
- 3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-methylbenzenesulfonamide;
- 4-((2-(4-fluorophenyl)-4-methoxypiperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole;
- (1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-2-yl)methanol;
- (4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanol;
- 5,7-dimethyl-4-((2-(4-(methylsulfonyl)phenyl)piperidin-1-yl)methyl)-1*H*-indole;
- 4-((2-(4-(2*H*-tetrazol-5-yl)phenyl)piperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole;
- 1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-4-amine;
- 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
- 4-(1-((5-chloro-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
- 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzamide;

4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzamide;

4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-hydroxypiperidin-2-yl)benzoic acid;

4-(1-((5-chloro-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;

methyl 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate;

4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-2-fluorobenzoic acid;

4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)pyrrolidin-2-yl)benzoic acid;

5-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)picolinic acid;

4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-3-methoxybenzoic acid;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;

5-methoxy-7-methyl-4-((2-(pyridin-4-yl)piperidin-1-yl)methyl)-1*H*-indole;

5-methoxy-7-methyl-4-((2-(pyridin-3-yl)piperidin-1-yl)methyl)-1*H*-indole;

3-fluoro-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;

4-(4-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)morpholin-3-yl)benzoic acid;

6-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)nicotinic acid;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-propoxypiperidin-2-yl)benzoic acid;

4-(4-hydroxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-3-methylbenzoic acid;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-5-methylpiperidin-2-yl)benzoic acid;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-ethylpiperidin-2-yl)benzoic acid;

2-(4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)acetic acid;

2-(3-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)acetic acid;

5-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)picolinic acid;

2-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)thiazole-4-carboxylic acid;

2-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-4-methylthiazole-5-carboxylic acid;

3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)azepan-2-yl)benzoic acid;

4-((2-(4-(1*H*-pyrazol-4-yl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;

4-((2-(4-(1*H*-pyrazol-3-yl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-1-naphthoic acid;

1-(2,2,2-trifluoro-1-(5-methoxy-7-methyl-1*H*-indol-4-yl)ethyl)piperidin-2-yl)benzoic acid;

2-methoxy-4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;

2-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-2-phenylpiperidin-4-yl)acetonitrile;

4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoic acid;

4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
 5-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)picolinic acid;
 4-(1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4,4-dimethylpiperidin-2-yl)benzoic acid;
 4-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzonitrile;
 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
 4-((4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic acid;
 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
 4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
 4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic acid;
 4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
 4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic acid;
 4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
 4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
 4-(5-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
 4-(5-hydroxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;
 1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)-*N*-methyl-2-phenylpiperidin-4-amine;
 (4-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanamine;
 (4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanol;
 4-((2-(3-(2*H*-tetrazol-5-yl)phenyl)piperidin-1-yl)methyl)-5,7-dimethyl-1*H*-indole;
 3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;
 (3-(1-((5,7-dimethyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)methanol;
 (4-((2-(4-(1*H*-tetrazol-5-yl)phenyl)-4-ethoxypiperidin-1-yl)methyl)-5-methoxy-7-methyl-1*H*-indole;
 4-(4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-(methylsulfonyl)benzamide;
 4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-methylbenzamide;
 4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N,N*-dimethylbenzamide;
 (4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)phenyl)(morpholino)methanone;
N-(2-hydroxyethyl)-4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzamide;

4-(4-methoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)-*N*-(2-methoxyethyl)benzamide;

N-((4-(1-((5-cyclopropyl-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-

yl)phenyl)sulfonyl)acetamide; 4-(6-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-6-azaspiro[2.5]octan-5-yl)benzoic acid;

4-ethyl-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;

ethyl 4-((2*S*,4*R*)-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)-4-methylpiperidin-2-yl)benzoate; ethyl 4-((2*S*,4*S*)-4-ethoxy-1-((5-methoxy-7-methyl-1*H*-indol-4-yl)methyl)piperidin-2-yl)benzoate and salts, stereoisomers and tautomers thereof.

16. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and a therapeutically effective amount of a compound of any one of claims 1-15.

17. A combination, in particular a pharmaceutical combination, comprising a therapeutically effective amount of the compound according to any one of claims 1-15 and a second therapeutically active agent.

18. A therapeutically effective amount of the compound according to any one of claims 1-15 for use in modulating the activity of the complement alternative pathway activity in a subject.

19. A therapeutically effective amount of the compound according to any one of claims 1-15 for use in the treatment of a disorder or a disease in a subject mediated by complement activation, in particular mediated by activation of the complement alternative pathway.

20. The compound of claim 19, in which the disease or disorder is selected from the group consisting of age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-choroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus, nonarteritic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of inappropriate or undesirable complement activation, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in

cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, neural regeneration, dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis and obesity.

21. A compound of any one of claims 1-15 for use in the treatment of age related macular degeneration.
22. A compound according to any one of claims 1-15, for use as a medicament.
23. Use of a compound according to any one of claims 1-15, in the manufacture of a medicament for the treatment of a disorder or disease in a subject mediated by complement activation or activation of the complement alternative pathway.
24. The use of claim 23, in which the disease or disorder is selected from the group consisting of age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-choroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus, nonarteritic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of inappropriate or undesirable complement activation, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, neural regeneration, dyspnea, hemoptysis, ARDS,

asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis and obesity.

25. Use of a compound according to any one of claims 1-15, in the manufacture of a medicament for the treatment of age-related macular degeneration.

26. A compound of claim 1 to 15 for use in the treatment of age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-choroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus, nonarteritic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of inappropriate or undesirable complement activation, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, neural regeneration, dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis and obesity.